CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs)

被引：0
|
作者：
Albiges, Laurence
Schmidinger, Manuela
Pioger, Naila Taguieva
Perol, David
Gruenwald, Viktor
机构：
[1] Univ Paris Saclay, Med Oncol, Villejuif, France
[2] Med Univ Vienna, Vienna, Austria
[3] Ipsen Pharma, Boulogne, France
[4] Ctr Leon Berard, Dept Clin Res, Lyon, France
[5] Hannover Med Sch, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, Hannover, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS772
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Escudier, Bernard
    Esteban, Emilio
    Bjarnason, Georg A.
    Lim, Ho Yeong
    Pittman, Kenneth B.
    Senico, Peggy
    Niethammer, Andreas
    Lu, Dongrui Ray
    Hariharan, Subramanian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 760 - +
  • [32] Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
    Govindan, R.
    Zergebel, C.
    Saito, K.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma
    Krysanov, I. S.
    Krysanova, V. S.
    Alekseev, B. Ya
    Ermakova, V. Yu
    Gameeva, E., V
    ONKOUROLOGIYA, 2020, 16 (02): : 52 - 64
  • [34] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [35] Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
    Procopio, Giuseppe
    Derosa, Lisa
    Gernone, Angela
    Morelli, Franco
    Sava, Teodoro
    Zustovich, Fable
    De Giorgi, Ugo
    Ferrari, Vittorio
    Sabbatini, Roberto
    Gasparro, Donatello
    Felici, Alessandra
    Burattini, Luciano
    Calvani, Nicola
    Lo Re, Giovanni
    Banna, Giuseppe
    Brizzi, Maria Pia
    Rizzo, Mimma
    Ciuffreda, Libero
    Iacovelli, Roberto
    Ferrau, Francesco
    Taibi, Eleonora
    Bracarda, Sergio
    Porta, Camillo
    Galligioni, Enzo
    Contu, Antonio
    FUTURE ONCOLOGY, 2014, 10 (10) : 1741 - 1750
  • [36] A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
    Shen, L.
    Ajani, J. A.
    Kim, S-B.
    Van Cutsem, E.
    Guo, B.
    Song, J.
    Paton, V.
    Kato, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.
    Verzoni, Elena
    Bearz, Alessandra
    De Giorgi, Ugo
    Nole, Franco
    Porta, Camillo
    Ratta, Raffaele
    Claps, Melanie
    Pagani, Filippo
    Martinetti, Antonia
    Cova, Agata
    Rivoltini, Licia
    De Braud, Filippo G.
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
    Gruenwald, Viktor
    Hilser, Thomas
    Meiler, Johannes
    Goebell, Peter J.
    Ivanyi, Philipp
    Strauss, Arne
    Hartmann, Arndt
    Bedke, Jens
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 272 - 280
  • [39] Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Nohara, Takahiro
    Izumi, Kouji
    Anai, Satoshi
    Fujimoto, Kiyohide
    Koguchi, Tomoyuki
    Ishibashi, Kei
    Kawai, Noriyasu
    Nakane, Keita
    Iba, Akinori
    Masumori, Naoya
    Takahara, Shizuko
    Mizokami, Atsushi
    CANCERS, 2023, 15 (10)
  • [40] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
    Choueiri, Toni K.
    McDermott, David F.
    Merchan, Jaime
    Bauer, Todd M.
    Figlin, Robert
    Heath, Elisabeth, I
    Michaelson, M. Dror
    Arrowsmith, Edward
    D'Souza, Anishka
    Zhao, Song
    Roy, Ananya
    Perini, Rodolfo
    Vickery, Donna
    Tykodi, Scott S.
    LANCET ONCOLOGY, 2023, 24 (05): : 553 - 562
12345